LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
| Autor: | Robert, C., Milhem, M.M., Sacco, J.J., Michels, J., In, G.K., Muñoz-Couselo, E., Schadendorf, D., Beasley, G.M., Niu, J.J., Chmielowski, B., Wise-Draper, T.M., Bowles, T.L., Tsai, K.K., Lebbe, C., Gaudy Marqueste, C., Middleton, M.R., Samson, A., Zhu, J., Viana, M., Wong, M.K.K. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S1236-S1237 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|